SMI developer Resyca has announced the appointment of former Proveris Scientific Sales Director for Europe and India Deborah Jones as its new CEO, following the resignation of Remko Beimers. Jones joined Proveris in 2016 after having served in sales and management positions at Equivital and ADInstruments. According to Resyca, “Her focus will be on enabling more efficient, patient-friendly drug delivery and strengthening Resyca’s position as a trusted partner in integrated drug–device combination development.”
Resyca, which is a joint venture between Bespak and Medspray, offers soft mist inhaler and soft mist nasal device development. Resyca and Aero Pump announced a partnership on the Ultra Soft Nasal Pump Spray in October 2024. In March 2025, the company announced a licensing agreement with Cyrano Therapeutics for delivery of Cyrano’s CYR-064 intranasal theophylline via Resyca’s soft mist nasal spray technology.
Jones commented, “I am excited to join Resyca at such a pivotal time in the evolution of inhaled and nasal drug delivery. Soft mist technologies represent a significant step forward in optimizing drug deposition, improving ease of use, and enhancing dose consistency. With Resyca’s technologies, we can improve adherence, therapeutic effectiveness, and ultimately patient outcomes.”
Read the Resyca press release
